SGRL

Ankleshwar, India Founded: 1995 • Age: 31 yrs Listed
Manufacturer of pharmaceutical drug intermediates for API and fine chemical industry
Request Access
Report Incorrect Data
Page last updated

About SGRL

SGRL is a publicly listed company based in Ankleshwar (India) founded in 1995 by Chanudubhai Manubhai Kothia. The company has 149 employees. Its chief executive, as recorded, is Chanudubhai Manubhai Kothia. Its Indian entity Shree Ganesh Remedies Limited reported revenue of ₹112 Cr. SGRL offers products and services including Bis(2-chloroethyl)amine hydrochloride, 4-Chloro-4-fluorobutyrophenone, Diphenylacetonitrile, Trityl chloride, and 2-Furoyl chloride. Its focus areas include Biopharma Outsourcing, CDMO, Small Molecules & Peptides and API Production. Similar companies include Laurus Labs, Symbiotec and SeQuent; 2 of its 3 listed similar companies have raised funding.

Company details

Manufacturer of pharmaceutical drug intermediates for API and fine chemical industry. It is a healthcare company offering manufacturing of pharmaceutical intermediates and fine chemicals including anti depressant, diabetic, cancer, fungal arrhythmic and more API intermediates.

  • Headquarters Ankleshwar, India
  • Employees 149
  • Founders Chanudubhai Manubhai Kothia
  • Stage Public
  • Sectors
    Healthcare
  • Email
    ••••••••
  • Phone
    •••• ••••
  • Website ganeshremedies.com
  • Social LinkedIn X Facebook YouTube
  • Legal Name Shree Ganesh Remedies Ltd.
Operational Areas
Healthcare → Biopharma Outsourcing & Drug Delivery
Key Metrics
  • Market Cap
    ₹821 Cr

    SGRL · NSE

  • Share Price
    ₹617.25

    -3.52% today

  • Revenue
    ₹109 Cr

    FY 2025-26 · +0.6% YoY

  • EBITDA
    ₹35.01 Cr

    Margin 32.0%

  • Net Profit
    ₹16.56 Cr

    FY 2025-26 · -26.2% YoY

  • P/E (TTM)
    54.7x

    P/B 5.2x

  • ROE
    11.5%

    ROCE 14.6%

  • Debt / Equity
    0.22

    Interest cover 14.5x

  • Employee Count
    149

Products & Services of SGRL

SGRL offers a comprehensive portfolio of products and services, including Bis(2-chloroethyl)amine hydrochloride, 4-Chloro-4-fluorobutyrophenone, Diphenylacetonitrile, Trityl chloride, and 2-Furoyl chloride.

Bis(2-chloroethyl)amine hydrochloride
Chemical Intermediate

Intermediate for pharmaceutical synthesis and reactions.

4-Chloro-4-fluorobutyrophenone
Fine Chemical

Used in drug manufacturing processes.

Diphenylacetonitrile
Specialty Chemical

Component for API intermediates.

Trityl chloride
Pharma Intermediate

Essential for organic synthesis in pharmaceuticals.

2-Furoyl chloride
Chemical Reagent

Applied in fine chemical production.

Apps and channels of SGRL

its YouTube channel Shree Ganesh Remedies Limited has 57 subscribers and 5 videos.

Shree Ganesh Remedies Limited
YouTube 57 subscribers 5 videos Science & Technology
Open channel

Videos from SGRL

The most watched videos on SGRL's YouTube channel, Shree Ganesh Remedies Limited (57 subscribers). Click a video to play it here.

Pharmaceutical Intermediates Manufacturer in India
281 views
High Quality Bis(2-chloroethyl)amine hydrochloride
206 views
Leading Drug Intermediates Manufacturer in India
190 views
The Best Pharmaceutical Intermediaries Provider
154 views

More on Shree Ganesh Remedies Limited.

Board of directors of Shree Ganesh Remedies Limited (SGRL)

Shree Ganesh Remedies Limited is the primary company behind SGRL. The boards of the 2 registered companies of SGRL currently have 8 directors; the longest-serving is Chandulal Manubhai Kothia, appointed in 1995. 15 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Chandulal Manubhai Kothia
DIN 00652806
Managing Director27 Apr 199531 yrs 6 moShree Ganesh Remedies Limited
Ketan Hasmukhbhai Kothia
DIN 03259744
Designated Partner24 Jan 20206 yrs 9 moKothia Corporation Llp
Parth Chandulal Kothia
DIN 08830608
Whole-time director18 Jan 20215 yrs 9 moShree Ganesh Remedies Limited
Hasmukhbhai Manubhai Kothia
DIN 01076206
Designated Partner17 Aug 20215 yrs 2 moKothia Corporation Llp
Maulikkumar Jaysukhbhai Sudani
DIN 06464415
Director31 Jul 20233 yrs 3 moShree Ganesh Remedies Limited
Parulben Sahani
DIN 10198882
Director31 Jul 20233 yrs 3 moShree Ganesh Remedies Limited
Shruti Rajesh Sohane
DIN 10899663
Director08 Aug 20251 yr 2 moShree Ganesh Remedies Limited
Hiral Nandkishorbhai Shah
DIN 07164025
Director17 Jul 20263 moShree Ganesh Remedies Limited

People of SGRL

1 people are tracked at SGRL (1 in leadership); the tracked headcount is 149.

NameRoleGroup
Chanudubhai Manubhai Kothia
Founder & CEO & Managing DirectorLeadership
Premium access

Complete people profiles for SGRL

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of SGRL

SGRL is a publicly listed company on the BSE with ticker symbol SGRL in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date13 Oct 2017
  • Listed onBSE: 540737
  • Listed entityShree Ganesh Remedies Ltd.
  • Exchange sectorHealth technology
  • ISININE414Y01015
  • Share price₹517.10 (-3.53% on the day) · 2026-05-11
  • Market capitalisation₹681 Cr
  • Price to earnings36.7
  • EPS (diluted, trailing year)₹14.08
  • Volume (last session)3,006
  • Analyst consensusNo rating

Financials of SGRL

Exchange-reported figures of Shree Ganesh Remedies Limited, the listed company behind SGRL (NSE: SGRL).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹109 Cr
+0.6% YoY
EBITDA
₹35.01 Cr
-10.7% YoY
Profit After Tax
₹16.56 Cr
-26.2% YoY
Net Worth
₹163 Cr
+12.3% YoY
Total Assets
₹194 Cr
+5.6% YoY
Total Debt
₹30.81 Cr
-19.7% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2019-20FY 2018-19
Income statement
Revenue10910912664.0235.31
Revenue growth+0.6%-13.7%-+81.3%-
EBITDA35.0139.2241.8012.528.74
EBITDA margin+32.0%+36.1%+33.2%+19.6%+24.8%
Profit before tax24.0131.2738.1513.608.67
Net profit16.5622.4527.9710.486.24
Net profit margin+15.2%+20.7%+22.2%+16.4%+17.7%
EPS (₹)13.8317.9721.8911.676.95
Balance sheet
Total assets19418415946.8934.73
Net worth16314512242.2033.82
Total debt30.8138.3936.454.470.75
Cash & bank13.4810.0316.262.331.00
Net working capital61.1751.9154.0522.7115.52
Cash flow
Cash from operations23.7430.6630.454.59(5.22)
Cash from investing(8.60)(35.48)(33.09)(2.91)(0.08)
Cash from financing(11.70)(1.09)9.84(0.48)(0.18)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue14.3633.2021.1130.3224.6724.4327.0532.33
Revenue growth (YoY)-41.8%+35.9%-22.0%-6.2%-0.4%---
Other income0.941.020.660.690.662.290.710.19
EBITDA3.3511.386.739.627.309.889.9011.31
EBITDA margin+23.3%+34.3%+31.9%+31.7%+29.6%+40.4%+36.6%+35.0%
Depreciation2.442.802.672.592.422.422.702.42
Interest0.320.880.741.010.940.970.390.44
Profit before tax1.538.723.986.714.608.787.528.64
Tax0.422.460.891.761.152.182.102.23
Net profit1.116.263.094.953.456.605.426.41
EPS (₹)0.874.882.413.862.685.134.224.97
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue10910912691.3671.2949.0858.43
Revenue growth+0.6%-13.7%+37.8%+28.2%+45.3%-16.0%-
EBITDA35.0139.2241.8023.4317.9313.6410.96
EBITDA margin+32.0%+36.1%+33.2%+25.7%+25.2%+27.8%+18.8%
Profit before tax24.0131.3038.1620.2318.0112.9312.76
Net profit16.6922.4827.9815.1613.439.749.64
Net profit margin+15.3%+20.7%+22.2%+16.6%+18.8%+19.9%+16.5%
EPS (₹)13.8417.9921.8912.1411.169.7510.73
Balance sheet
Total assets19418415912061.7850.3944.59
Net worth16314512287.2061.5850.0142.09
Total debt30.8138.3936.4533.010.000.212.32
Cash & bank13.459.9916.1911.543.883.471.75
Net working capital61.1451.8753.9844.6829.8624.8920.37
Cash flow
Cash from operations23.7530.6630.4517.1013.423.313.88
Cash from investing(8.60)(35.48)(33.18)(50.98)(11.91)(0.94)(2.91)
Cash from financing(11.70)(1.06)9.8538.66(1.09)(0.66)(0.21)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue14.3633.2021.1130.3224.6724.4327.0532.33
Revenue growth (YoY)-41.8%+35.9%-22.0%-6.2%-0.4%---
Other income0.941.020.660.690.662.290.710.19
Total expenses11.0121.8214.3820.7017.3714.5517.1521.02
EBITDA3.3511.386.739.627.309.889.9011.31
EBITDA margin+23.3%+34.3%+31.9%+31.7%+29.6%+40.4%+36.6%+35.0%
Depreciation2.442.802.672.592.422.422.702.42
Interest0.320.880.741.010.940.960.380.43
Profit before tax1.538.723.986.714.608.797.538.65
Tax0.422.450.891.761.152.182.102.23

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 31 Oct 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue14.3633.2021.1130.3224.6724.4327.0532.33
Revenue growth (YoY)-41.8%+35.9%-22.0%-6.2%-0.4%---
Other income0.941.020.660.690.662.290.710.19
EBITDA3.3511.386.739.627.309.889.9011.31
EBITDA margin+23.3%+34.3%+31.9%+31.7%+29.6%+40.4%+36.6%+35.0%
Depreciation2.442.802.672.592.422.422.702.42
Interest0.320.880.741.010.940.970.390.44
Profit before tax1.538.723.986.714.608.787.528.64
Tax0.422.460.891.761.152.182.102.23
Net profit1.116.263.094.953.456.605.426.41
EPS (₹)0.874.882.413.862.685.134.224.97
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2019-20FY 2018-19
Revenue10910912664.0235.31
Revenue growth+0.6%-13.7%-+81.3%-
Other income3.033.733.073.911.17
Total expenses74.2869.3884.1051.5026.57
Employee cost11.4010.128.412.901.63
EBITDA35.0139.2241.8012.528.74
EBITDA margin+32.0%+36.1%+33.2%+19.6%+24.8%
Depreciation10.479.576.112.291.04
Interest3.562.110.610.540.20
Profit before tax24.0131.2738.1513.608.67
Tax6.258.2010.053.122.43
Net profit16.5622.4527.9710.486.24
Net profit margin+15.2%+20.7%+22.2%+16.4%+17.7%
EPS (₹)13.8317.9721.8911.676.95
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2019-20FY 2018-19
Equity & liabilities
Share capital12.8412.8412.848.978.97
Reserves & surplus15013210933.2324.85
Shareholders' funds (net worth)16314512242.2033.82
Minority interest0.000.000.000.040.00
Secured loans30.6538.2335.602.120.57
Unsecured loans0.160.160.852.350.18
Total debt30.8138.3936.454.470.75
Total liabilities19418415946.8934.73
Assets
Gross block14812810534.6321.05
Net block10595.0080.5520.1314.50
Capital work in progress12.868.7816.920.000.00
Investments12.5318.344.743.074.05
Inventories24.0122.0224.996.416.51
Sundry debtors32.5722.2720.3317.799.72
Cash & bank balances13.4810.0316.262.331.00
Loans & advances3.365.003.954.294.58
Total current assets73.4259.3265.5330.8221.81
Total current liabilities12.257.4111.488.116.29
Net working capital61.1751.9154.0522.7115.52
Total assets19418415946.8934.73
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2019-20FY 2018-19
Opening cash9.9515.858.661.136.46
Net cash from operating activities23.7430.6630.454.59(5.22)
Net cash from investing activities(8.60)(35.48)(33.09)(2.91)(0.08)
Net cash from financing activities(11.70)(1.09)9.84(0.48)(0.18)
Net change in cash3.45(5.91)7.201.20(5.47)
Closing cash13.4810.0316.262.331.00
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2019-20FY 2018-19
Growth
Sales growth+0.6%-13.7%-+81.3%-
EBITDA growth-10.7%-6.2%-+43.3%-
PBT growth-23.2%-18.0%+180.5%+56.9%+9997.0%
Net income growth-26.2%-19.7%-+68.0%-
Revenue CAGR (3Y)+19.5%+45.4%---
EBITDA CAGR (3Y)+40.9%+64.9%---
Profitability & leverage
Net income margin+16.3%+21.2%+22.3%+16.4%+17.7%
Return on capital employed+14.6%+19.5%+24.4%+34.7%+25.5%
Return on net worth+11.5%+17.3%+23.0%+27.6%+18.5%
Debt / equity0.220.280.300.070.02
Long-term debt / equity0.170.220.240.030.01
Interest cover14.517.121.715.282.60
Efficiency & per share
Fixed asset turnover0.790.931.202.301.68
Inventory turnover4.754.625.049.915.42
Debtors turnover3.995.106.194.653.63
EPS (₹)13.8317.9721.8911.676.95
Dividend per share (₹)0.000.000.501.501.25
Book value per share (₹)126.95113.0795.0747.0437.70
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue14.3633.2021.1130.3224.6724.4327.0532.33
Revenue growth (YoY)-41.8%+35.9%-22.0%-6.2%-0.4%---
Other income0.941.020.660.690.662.290.710.19
Total expenses11.0121.8214.3820.7017.3714.5517.1521.02
EBITDA3.3511.386.739.627.309.889.9011.31
EBITDA margin+23.3%+34.3%+31.9%+31.7%+29.6%+40.4%+36.6%+35.0%
Depreciation2.442.802.672.592.422.422.702.42
Interest0.320.880.741.010.940.960.380.43
Profit before tax1.538.723.986.714.608.797.538.65
Tax0.422.450.891.761.152.182.102.23
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue10910912691.3671.2949.0858.43
Revenue growth+0.6%-13.7%+37.8%+28.2%+45.3%-16.0%-
Other income3.033.733.070.723.572.094.18
Total expenses74.2869.3884.1067.9353.3635.4447.47
Employee cost11.4010.128.415.972.952.432.17
EBITDA35.0139.2241.8023.4317.9313.6410.96
EBITDA margin+32.0%+36.1%+33.2%+25.7%+25.2%+27.8%+18.8%
Depreciation10.479.576.113.743.342.732.24
Interest3.562.080.600.180.150.070.14
Profit before tax24.0131.3038.1620.2318.0112.9312.76
Tax6.248.2010.055.064.613.193.12
Net profit16.6922.4827.9815.1613.439.749.64
Net profit margin+15.3%+20.7%+22.2%+16.6%+18.8%+19.9%+16.5%
EPS (₹)13.8417.9921.8912.1411.169.7510.73
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital12.8412.8412.8412.5112.0110.018.97
Reserves & surplus15013210974.6949.5740.0033.12
Shareholders' funds (net worth)16314512287.2061.5850.0142.09
Secured loans30.6538.2335.6031.440.000.172.12
Unsecured loans0.160.160.851.570.000.040.20
Total debt30.8138.3936.4533.010.000.212.32
Total liabilities19418415912061.7850.3944.59
Assets
Gross block14812810576.6642.0730.3325.12
Net block10595.0080.5558.0427.1918.8516.27
Capital work in progress12.868.7816.9215.403.092.050.00
Investments12.6218.424.820.080.083.197.10
Inventories24.0122.0224.9918.1813.6412.715.50
Sundry debtors32.5722.2720.3328.1418.3813.3316.63
Cash & bank balances13.459.9916.1911.543.883.471.75
Loans & advances3.365.003.954.369.005.363.88
Total current assets73.3959.2865.4662.2244.9034.8727.76
Total current liabilities12.257.4111.4817.5415.049.987.39
Net working capital61.1451.8753.9844.6829.8624.8920.37
Total assets19418415912061.7850.3944.59
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash9.9015.788.663.883.471.750.99
Net cash from operating activities23.7530.6630.4517.1013.423.313.88
Net cash from investing activities(8.60)(35.48)(33.18)(50.98)(11.91)(0.94)(2.91)
Net cash from financing activities(11.70)(1.06)9.8538.66(1.09)(0.66)(0.21)
Net change in cash3.46(5.88)7.124.770.421.710.76
Closing cash13.459.9916.1911.543.883.471.75
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+0.6%-13.7%+37.8%+28.2%+45.3%-16.0%-
EBITDA growth-10.7%-6.2%+78.4%+30.7%+31.5%+24.5%-
PBT growth-23.3%-18.0%+88.6%+12.3%+39.3%+1.3%+47.3%
Net income growth-25.8%-19.7%+84.6%+12.9%+37.9%+1.0%-
Revenue CAGR (3Y)+6.2%+15.1%+36.9%+16.1%+26.4%+21.7%+43.3%
EBITDA CAGR (3Y)+14.3%+29.8%+45.3%+28.8%+27.1%+38.0%+39.0%
Profitability & leverage
Net income margin+16.3%+21.3%+22.3%+16.6%+18.8%+19.9%+16.5%
Return on capital employed+14.6%+19.5%+27.8%+22.4%+32.4%+27.4%+32.5%
Return on net worth+11.5%+17.3%+26.9%+20.4%+24.0%+21.2%+25.4%
Debt / equity0.220.280.330.220.000.030.04
Long-term debt / equity0.170.220.290.200.000.000.00
Interest cover14.517.021.680.911.030.641.61
Efficiency & per share
Fixed asset turnover0.790.931.381.541.971.772.53
Inventory turnover4.754.625.835.745.415.399.73
Debtors turnover3.995.105.193.934.503.284.43
EPS (₹)13.8417.9921.8912.1411.169.7510.73
Dividend per share (₹)0.000.000.500.300.501.751.50
Book value per share (₹)126.98113.1095.0769.7051.2849.9746.92

Similar companies to SGRL

SGRL has 3 listed similar companies in our database, 2 of them funded. They include Laurus Labs, Symbiotec and SeQuent.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
Laurus Labs
lauruslabs.com2005Hyderabad, India$229.73M6,035
Pharmaceutical and biotechnology company
Symbiotec
symbiotec.in2002Indore, India$61.01M1,822
Non-sterile steroid hormone-based APIs and intermediates are manufactured.
SeQuent
sequent.in2002Bengaluru, India
APIs are developed and manufactured for therapeutic areas.
Premium access

Detailed similar companies of SGRL

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of SGRL

The website of SGRL (ganeshremedies.com) receives about 3.3K visits a month.

  • Monthly visits
    3.3K

    ▼ 46.7% vs previous month

Similar websites

Websites whose visitors overlap most with SGRL. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
Speciality Chemicals Magazine
specchemonline.com
100%
#1,875,513View details
Anantlabs
anantlabs.com
98%
#5,593,490View details
Inventys
inventys.in
87%
1.4K#10,234,713View details
Lifecare Neuro Products
lifecareneuro.com
86%
3.3K#5,271,357View details

Top companies in Biopharma Outsourcing & Drug Delivery

3 companies that operate in the same segment as SGRL (Biopharma Outsourcing & Drug Delivery) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Anthem Biosciences
Developer of integrated contract research development and manufacturing services
2007Bengaluru, Karnataka, IndiaUSD 35.74 MUSD 226.38 M1,820
Laurus Labs
Pharmaceutical and biotechnology company
2005Hyderabad, Telangana, IndiaUSD 229.73 MUSD 726.15 M12,470
Entero Healthcare
India's leading healthcare products distribution platform
2018Mumbai, Maharashtra, IndiaUSD 59.67 MUSD 702.49 M4,260
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Sgrl

Shree Ganesh Remedies consolidated net profit declines 67.54% in the June 2026 quarter | Capital Market News - Business Standard
Business Standard • 2 months ago
Shree Ganesh Remedies consolidated net profit declines 25.81% in the June 2025 quarter | Capital Market News - Business Standard
Business Standard • 1 year ago
Music Broadcast Ltd leads losers in 'B' group | Capital Market News - Business Standard
Business Standard • 1 year ago
Shree Ganesh Remedies consolidated net profit declines 47.66% in the March 2025 quarter | Capital Market News - Business Standard
Business Standard • 1 year ago
Shree Ganesh Remedies standalone net profit rises 30.46% in the September 2022 quarter
India Infoline • 1 year ago
Shree Ganesh Remedies Receipt Revocation Of Closure Direction By Gujarat Pollution Control Board
Reuters • 2 years ago
Shree Ganesh Remedies Says Incorporated Unit "SGRL USA INC"
Reuters • 3 years ago
Shree Ganesh Remedies Names Parth Kothia As CFO
Reuters • 3 years ago
Shree Ganesh Remedies Re-Appoints Chandulal Manubhai Kothia As MD
Reuters • 4 years ago
Shree Ganesh Remedies Highest Bidder For Asset Auction Of Jaiswal Pharmachem
Reuters • 4 years ago
Premium access

Complete news archive for SGRL

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about SGRL

SGRL was founded in 1995.

SGRL is headquartered in Ankleshwar, India. It is registered at Ankleshwar, Gujarat, India.

Chanudubhai Manubhai Kothia is the CEO of SGRL, as recorded in our data. They have also founded this company.

SGRL has 149 employees.

The primary company behind SGRL, Shree Ganesh Remedies Limited, reported revenue of ₹112 Cr for FY 2026, up 1% year on year.

Manufacturer of pharmaceutical drug intermediates for API and fine chemical industry. It is a healthcare company offering manufacturing of pharmaceutical intermediates and fine chemicals including anti depressant, diabetic, cancer, fungal arrhythmic and more API intermediates.

SGRL's top competitors include Laurus Labs, Symbiotec and SeQuent.

SGRL offers Bis(2-chloroethyl)amine hydrochloride, 4-Chloro-4-fluorobutyrophenone, Diphenylacetonitrile, Trityl chloride, and 2-Furoyl chloride.

Yes, SGRL is publicly traded on BSE under the ticker symbol SGRL.

SGRL is associated with 2 legal entities: Shree Ganesh Remedies Limited, Kothia Corporation Llp.

The legal entities of SGRL currently have 9 directors, including Hasmukhbhai Manubhai Kothia, Ketan Hasmukhbhai Kothia, Chandulal Manubhai Kothia and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available